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Background/aim: Currently, the provision of blood products largely depends on walking blood banks and limited amounts of stored
blood with short shelf lives. We aimed to compare the efficacy of erythrocyte concentrate (ECs) by pre- and postfreezing in vitro tests.
Materials and methods: In our study, 10 ECs were glycerolized, frozen, thawed, and then deglycerolized using the Naval Blood
Research Laboratory method. In addition to using the standard tests, ATP and 2,3-DPG levels and the viability of erythrocytes were
also determined.
Results: The prefreezing mean viability rates of erythrocytes changed from 89.7 ± 13.7% to 98.6 ± 1.8% after thawing and deglycerolization.
Prefreezing and day 0 ATP levels (1.64 ± 0.15 µmol/g Hb and 1.81 ± 0.14 µmol/g Hb, respectively) were similar. The 2,3-DPG levels
decreased from 18.09 ± 4.78 µmol/g Hb measured before the procedure to 10.41 ± 4.58 µmol/g Hb on day 0. The mean hemolysis rates
and supernatant Hb levels changed from 0.21 ± 0.11% to 0.36 ± 0.12% and 1 ± 0.5 g/L to 1.5 ± 0.5 g/L, respectively.
Conclusion: The test results showed the efficacy of the frozen-thawed ECs to be used in humans for a broad spectrum of clinical
indications. As a part of a contingency plan, national frozen blood reserves need to be established.
Key words: Cryopreservation, erythrocyte concentrates, blood transfusion, flow cytometric analysis

1. Introduction
Freezing erythrocytes was first attempted by FélixArchimède Pouchet in 1866, and fractionation after
thawing was reported (1). In 1950, Smith postulated
that glycerol could prevent erythrocyte damage due to
freezing and was the first to freeze erythrocytes without
glycerol-related loss of cell function. Mollison, using the
system discovered by Smith, performed the first successful
transfusion of frozen erythrocyte concentrate (EC) in
1951 (2–4). The US Food and Drug Administration (FDA)
approval for frozen ECs with glycerol to be stored for later
use at –80 °C for 10 years was announced in September
1987. In 2010, the EC shelf life was extended to 30 years in
European countries (5,6). Following the deglycerolization
of frozen ECs after years of storage, their shelf life can be
* Correspondence: soyilmaz@gata.edu.tr
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extended to 7 or 14 days by adding saline, adenine, glucose,
and mannitol (SAG-M) or AS-3 solution, respectively (7–
10).
The storage of frozen ECs has become an essential
part of national blood crisis policies in several countries,
as frozen ECs can be thawed and transfused rapidly in
emergency situations without the need for laboratory
tests. ECs are also cryopreserved for patients with rare
blood types and are autologous blood for patients with red
blood cell alloantibodies; clinical conditions that require
cytomegalovirus (–) blood can also be considered in this
context (11).
Although fresh ECs can be stored for up to 42 days by
introducing additive solutions, they can be preserved for
an extended time period by freezing in an efficient and
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reliable manner (11). Thus, cryopreservation of expired
ECs, instead of disposal, and their use after thawing can
not only prevent the inappropriate waste of resources but
will also allow the use of ECs in times of need.
This study presents the in vitro assay data of 10 ECs that
were frozen at –80 °C with 40% glycerol using the Naval
Blood Research Laboratory (NBRL) method and were
thawed after 24 h at the Blood Training Center and Blood
Bank of Gülhane Military Medical Academy. Additionally,
the need to establish the national blood policy of Turkey,
including the use of frozen ECs at times of peace and
war, was addressed by reviewing the experiences gained
by other countries during the historical development of
frozen ECs.
2. Materials and methods
After receiving ethical committee approval and informed
consent from all participants, 450-mL whole blood
donations from 10 donors were collected in 3 bags
(Kansuk Blood Bags with 63 mL of CPD anticoagulant,
CE 0197, Turkey). Whole blood samples were centrifuged
at 22 °C and 4000 rpm for 20 min using a Sorvall RC12BP
centrifuge (Thermo Scientific RC12BP, USA). Plasma was
extracted by using a bag press (Bioelettronica, Italy). ECs
were then transferred into Kansuk Blood Bags containing
100 mL of SAG-M.
White blood cell (WBC), hemoglobin (Hb), hematocrit
(Htc), pH, supernatant Hb, adenosine triphosphate
(ATP), and 2,3-diphosphoglycerate (2,3-DPG) levels and
the osmotic fragility and viability of ECs were analyzed
before the procedure, after deglycerolization (day 0),
and on day 14 of the storage of the thawed components
at 4–6 °C. SAG-M was separated before glycerolization
using an extractor following a 4-min centrifugation at 20
°C and 1623 RCF (× g). The ECs were weighed and Htc
measurements were recorded. The NBRL method was
used for glycerolization and deglycerolization (12).
2.1. Glycerolization
The 1-day-old ECs were glycerolized in a closed system
with 57.1% glycerol using the Haemonetics ACP 215 device
(glycerol 57.1% 500 mL, S.A.L.F Laboratorio Farmacologica,
Italy; Haemonetics RBC Glycerolization Set Ref 225, USA),
and the glycerolized ECs at the targeted concentration of
40% were obtained. To remove the excessive glycerol, a 10min centrifugation was performed at 20 °C and 1283 × g.
The excessive glycerol was transferred into an empty bag
using a Terumo sterile tubing welder (TSCD II, Terumo
Europa N.V., Belgium). Glycerolized ECs were placed
in a cardboard box and kept in deep-freeze (Arctiko AS
ULUF750, Denmark) at –80 °C for 24 h.
2.2. Deglycerolization
Frozen glycerolized ECs were thawed at 37 °C over a period
of 10–12 min (Helmer DH 8, USA). ECs were processed

using Haemonetics ACP 215 with 12% NaCl, 0.2%
glucose + 0.9% NaCl, and SAG-M solutions, respectively
(RBC De-Glycerol Ref 235, Haemonetics Corporation
USA; solution NaCl 12% from Bioluz Laboratoire
Pharmaceutique; solution glucose 0.2% + NaCl 0.9%
from Bioluz Laboratoire Pharmaceutique; SAG-M from
Haemonetics Corporation USA).
2.3. In vitro measurements
All biochemical analyses were performed at the Medical
Biochemistry Laboratory of Gülhane Military Medical
Academy. The blood cold-chain principles were strictly
followed. pH analyses were performed within 2 min after
collecting the samples using an ABL 835 FLEX blood
gas analyzer (Radiometer Medical ApS., Denmark).
The samples’ whole blood counts at the time of receipt
were performed using the ABX Pentra XL80 instrument
(HORIBA ABX SAS, France). The preparation of
resuspended erythrocytes and hemolysate was performed
in the method described by Erlandsen et al. (13). All the
samples, including supernatant and hemolysate, were kept
at –80 °C for ATP, 2,3-DPG, and supernatant hemoglobin
concentration measurements.
For the quantitative determination of hemolysate
ATP, the ENLITEN ATP Assay System Bioluminescence
Detection Kit (Promega Corporation, USA) was used. All
the processes were performed by following the instructions
of the kit. For the quantitative determination of hemolysate
2,3-DPG, the Cusabio Human 2,3-DPG ELISA Kit (CSBE09861h, CUSABIO, China) was used. All the processes
were performed by following the instructions of the kit.
The measurements of free hemoglobin concentrations
were performed according to the cyanomethemoglobin
method (14,15). Normal-level Hema-Trol Hb control
material (NERL HEMA-Trol Whole Blood HGB Controls,
Product Number HYC84667, Thermo Fisher Scientific
Inc., USA) was used as the standard. Following suitable
dilutions, the samples and standards were added to the
microplate with Drabkin’s solution in the wells. All the
standards and samples were analyzed in duplicate. The
Synergy HT Multi-Mode Microplate Reader and KC4
Software (BioTek Instruments Inc., USA) were used for
luminescence and optic density (absorbance) readings.
The formulation of Valeri et al. was used to calculate
hemolysis ratio before and after the steps (16).
Erythrocyte samples were transferred to 3-mL tubes
containing heparin and were mixed for the evaluation of
osmotic fragility. The quantitative tube method was used.
The NaCl concentration of the tube in which hemolysis
started was recorded. Presence of hemolysis at 0.45%–
0.55%, >0.55%, and ≤0.30% NaCl concentrations was
defined as normal, increased, and decreased osmotic
fragility, respectively.
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2.4. Erythrocyte identification and viability assessment
with flow cytometry
Erythrocyte samples were transferred to tubes containing K3
EDTA. The 2 µL-samples were transferred to a polystyrene
tube, 3 mL of phosphate buffer solution (PBS) was added,
and samples were resuspended and then washed twice at
1500 rpm for 10 min (following centrifugation, discarding
the supernatant, and resuspending the pellets underneath).
The pellet at the bottom was resuspended with 250–300
µL of PBS (Becton Dickinson, USA) and prepared for the
study. To label the erythrocytes, 2 µL of CD235a FITC (BD
Pharmingen, USA) was transferred to another polystyrene
tube to be studied, and 100 µL of the erythrocyte sample
was added. The cells were vortexed gently for 3 s and were
incubated in the dark at room temperature for 45 min. Vortex
was performed every 10 min. Cells with disturbed integrity
whose membranes became permeable and therefore not
viable were penetrated. A volume of 5 µL of cytoplasmstaining nucleic acid dye 7-aminoactinomycin D (7-ADD)
was added during the last 10 min of incubation (BD
Pharmingen). Following incubation, 500–600 µL of PBS was
added to prepare for analysis in flow cytometry. The samples
were analyzed using the FACSDiva software of FACSCanto
II model flow cytometry (BD Biosciences, USA). Viable
erythrocytes were identified as cells stained either positive
with CD235a FITC or negative with 7-ADD (Figure 1). A
total of 20,000 cells were counted for analysis, and the ratio
of viable erythrocytes was expressed as percentage.
3. Results
The mean Hb and Htc levels were 198 ± 21 g/L and 57.8
± 6.4%, respectively, in the before-procedure period.
The levels decreased to 144 ± 24 g/L and 43.9 ± 6.6%,
respectively, on day 0. The supernatant Hb levels that
denote the hemolysis ratio were similar in both the before-

procedure and the day 0 measurements (1 ± 0.5 g/L
and 1.5 ± 0.5 g/L, respectively); the day-14 supernatant
Hb levels were increased (3.5 ± 1.2 g/L). Accordingly,
hemolysis ratios calculated using supernatant Hb and Hb
measurements were increased on day 14 (Table 1).
Osmotic fragility test results in all 3 periods of the study
were similar to each other. The before-procedure mean
osmotic fragility was 0.57 ± 0.03, compared to 0.63 ± 0.02
and 0.67 ± 0.04 on days 0 and 14, respectively (Table 1).
Procedures that were performed during the
deglycerolization process resulted in leucodepletion, as
the before-procedure WBC count of (5.6 ± 3.2) × 109/L
decreased to (0.1 ± 0.04) × 109/L in the after-procedure
period. After the deglycerolization process, the mean pH
levels decreased from 7.0 ± 0.03 to 6.5 ± 0.02 (day 0) and
6.3 ± 0.04 (day 14) (Table 1).
ATP levels, among the criteria like 2,3-DPG that show
the oxygen-carrying capacity of erythrocytes, were similar
in the before-procedure period and on day 0 (1.81 ± 0.14
µmol/g Hb and 1.64 ± 0.15 µmol/g Hb, respectively).
However, 2,3-DPG levels were decreased in the afterprocedure period. Before the procedure, the mean 2,3DPG level was 18.09 ± 4.78 µmol/g Hb, compared to
10.41 ± 4.58 and 4.54 ± 3.23 µmol/g Hb on days 0 and 14,
respectively (Table 2).
3.1. Viable erythrocyte ratios assessment by flow
cytometric analysis
Before the procedure, the mean total erythrocyte percentage
was 86.7 ± 8.9%, compared to 98.5 ± 1% and 98.6 ± 0.6%
on days 0 and 14, respectively. Before the procedure, the
mean glycophorin A (+) cell percentage (CD235a) was 71.7
± 17.6%, versus 90.2 ± 7.8% and 81.7 ± 6% on days 0 and
14, respectively. Before the procedure, the mean 7-AAD (–)
(viable) cell percentage was 89.7 ± 13.7%, versus 98.6 ± 1.8%
and 10.6 ± 2.5% on days 0 and 14, respectively (Table 2).

B

C

FSC-A

SSC-A

FSC-A

7 AAD PerCP-A

A

CD235A FITC-A

7 AAD PerCP-A

Figure 1. Flow cytometric analysis of the erythrocytes. The location of all cells was determined based on
FSC (size) and SSC (granularity). A) Total erythrocyte population. B) Cells in the lower right quadrant
are cells carrying the glycophorin A antibody but not the 7-AAD antibody (viable). C) The P2 quadrant
shows live erythrocytes, while P3 peripheral shows nonviable erythrocytes with 7-AAD antibodies.
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Table 1. Hb levels, Htc levels, osmotic fragility, supernatant Hb levels, and hemolysis ratios of ECs before the procedure and on days 0
and 14. *B-p: Before procedure.

Cases

Hb, g/L

Htc, %

Osmotic fragility

Supernatant Hb conc., g/L Hemolysis, %

B-p.*

Day 0

Day 14 B-p.*

Day 0

Day 14 B-p.*

Day 0

Day 14 B-p.*

Day 0

Day 14 B-p.*

Day 0

Day 14

1

220

183

197

64.6

54.1

56

0.55

0.65

0.65

1.63

2.05

3.52

0.29

0.39

0.62

2

216

172

181

61.6

52

52.2

0.55

0.65

0.65

1.43

1.63

2.78

0.26

0.33

0.53

3

173

168

165

50

49.5

48.2

0.60

0.60

0.75

1.89

1.98

5.22

0.43

0.41

1.09

4

217

145

158

61.9

45.1

47.1

0.55

0.65

0.65

0.90

1.17

3.99

0.16

0.28

0.87

5

196

132

155

58.3

41.5

46.1

0.55

0.65

0.65

0.55

1.08

2.18

0.11

0.28

0.49

6

206

140

159

60

43

46.6

0.60

0.60

0.65

1.43

2.27

2.42

0.27

0.56

0.53

7

202

143

187

60.2

43.9

55.7

0.55

0.65

0.65

1.26

1.45

4.32

0.24

0.35

0.80

8

151

125

135

43.3

37.4

39

0.55

0.60

0.75

0.59

1.70

5.57

0.15

0.47

1.43

9

203

127

127

59.4

39.3

38.5

0.65

0.65

0.65

0.48

1.52

3.04

0.09

0.41

0.83

10

201

106

108

58.5

32.8

32.7

0.60

0.65

0.65

0.33

0.37

2.25

0.06

0.12

0.72

Mean

198

144

157

57.8

43.9

46.2

0.57

0.63

0.67

1.0

1.5

3.5

0.21

0.36

0.79

SD

21

24

28

6.4

6.6

7.6

0.03

0.02

0.04

0.5

0.5

1.2

0.11

0.12

0.29

Table 2. Glycophorin A (+) cell, total erythrocyte (CD235a), and viable erythrocyte [7-AAD (–)] percentages assessed by flow cytometry,
ATP, and 2,3-DPG levels of ECs before the procedure and on days 0 and 14. *B-p: Before procedure.

Cases

Total erythrocytes, %

7-AAD (–) erythrocytes
(viable erythrocytes), %

CD235a (+), %

ATP, µmol/g Hb

2,3-DPG, µmol/g Hb

B-p.*

Day 0

Day 14 B-p.*

Day 0

Day 14 B-p.*

Day 0

Day 14 B-p.*

Day 0

Day 14 B-p.*

Day 0

Day 14

1

80.3

97.7

99.5

97.1

92.4

92

99.7

99.9

7.6

1.629

1.601

0.888

26.208

4.195

1.693

2

92.1

99.4

97.5

94.1

92

83.1

91.9

99.6

12.1

1.644

1.428

0.735

18.687

11.599

8.487

3

78.8

98.5

98.5

69.9

91.7

84.8

99.5

99.4

6

1.817

1.532

0.418

14.481

13.141

3.411

4

75.8

95.9

99.5

61.7

69.5

81

98.6

96.9

12.2

1.674

1.570

0.738

17.756

14.410

8.491

5

86.8

98.6

98

83.6

95.9

69

99.6

99.3

11.4

1.82

1.618

0.371

22.242

13.331

8.302

6

97.6

99.7

98.3

75.7

96.4

80.2

98

99.8

10.5

1.915

1.822

0.847

11.764

8.578

4.849

7

87.7

99

98.6

52.2

90

79

99.2

98.7

11.9

2.043

1.583

0.835

23.025

18.505

1.016

8

74.8

98.5

98.9

68.5

87.2

86

67.2

99.2

9.3

1.748

1.569

0.637

19.723

9.147

6.708

9

97.1

99

98.6

74

93.5

84

68.8

99.6

10.3

1.977

1.916

0.718

13.031

5.194

1.086

10

96.4

99.3

98.8

40.2

94.1

78

74.7

94.1

14.9

1.807

1.786

0.716

14.002

6.049

1.355

Mean

86.7

98.5

98.6

71.7

90.2

81.7

89.7

98.6

10.6

1.81

1.64

0.69

18.09

10.41

4.54

SD

8.9

1

0.6

17.6

7.8

6

13.7

1.8

2.5

0.14

0.15

0.17

4.78

4.58

3.23

4. Discussion
There are currently 2 methods available for long-term
storage of erythrocytes: the low-glycerol method for
freezing blood products in liquid nitrogen at –196 °C, and

the high-glycerol method for storage at –80 °C (6). The
most commonly used EC-freezing technique is the highglycerol technique, which was defined by Valeri et al.; it
involves 40% (w/v) glycerolization of the erythrocytes
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followed by storage at –80 °C. When ready for use, the
frozen ECs are thawed and deglycerolized, which we also
did in our study (12).
Although this technique has been available for more
than 4 decades, it has never reached the desired popularity
due to its labor-intensiveness, cost, infrastructure
necessary for the procedure, maintenance, and limited
shelf life of thawed erythrocytes. However, this scenario
has been changed by the use of the NBRL method, which
has resulted in significantly less processing time and
increased shelf life, from 24 h to 14 days after thawing (17).
ATP and 2,3-DPG are important determinants of
erythrocyte O2 transport quality. Chaplin reported that the
frozen-thawed EC ATP levels were close in content to the
fresh donor EC levels (18). In our study, the ATP levels were
similar in both the before-procedure period and on day 0.
Our 2,3-DPG results on days 0 and 14 were lower when
compared to the before-procedure measurement (10.41 ±
4.58, 4.54 ± 3.23, and 18.09 ± 4.78 µmol/g, respectively).
Additionally, our day 0 results were in accordance with the
report of Valeri et al. which compared 4 different methods
of freezing ECs (12).
Supernatant Hb, hemolysis, pH, and osmotic fragility
levels in ECs were also examined in our study. Our
hemolysis percentages and supernatant Hb levels on
day 0 were close to the before-procedure levels. The
osmotic fragility ratios were increased on day 0. The
increased fragility ratios were due to factors (multiple
washings/centrifugation, use of cryoprotectant agent,
exposure to low temperature, hypertonic solutions during
deglycerolization, etc.) that decrease the membrane
stability. However, increased osmotic fragility ratios had
no effect on erythrocyte functions except for the decreased
shelf life after deglycerolization.
Htc and Hb levels of frozen ECs should be ≥38% and
36 g/dL, respectively, in order to meet the quality control
criteria of the ACP 215 system (http://www.nbrl.org/SOP/
ACP215/ACP215All.html). In our study, both Htc and Hb
levels met these criteria. Additionally, these findings were
close to the results of a multicenter study that assessed
the efficacy of EC processing with the ACP 215. After
deglycerolization, the mean pH level was 6.5 in our study.
This result was also in accordance with the pH test results
of this multicenter study (9).
In vivo and in vitro qualities of frozen ECs have
been well established by many studies (9,19). However,
viability of erythrocytes has also been studied by flow
cytometry analysis in our study. Interestingly, the mean
viability of erythrocytes was 89.7% before the procedure
and 98.6% on day 0. This result can also be attributed
to the repeated washing (5 times) of the cells during the
deglycerolization process. The washing process removes
nonviable erythrocytes, which may have contributed to
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the results observed in our study. The washing process also
removes biologically active substances that may contribute
to immunomodulatory effects in the recipients of blood
products and leads to significant reduction in transfusion
reactions (17).
WBC counts were <0.1×109/L. However, the flow
cytometry analysis showed that these cells counted by
the automated blood count instrument were not, in fact,
WBCs. The freezing process itself and repeated washings
of ECs decrease the WBCs as much as filtered ECs.
The AS-3 solution has been validated for a shelf life
of 14 days and was used in all other studies (8,9,11). To
our knowledge, only the SAG-M additive solution, which
is validated for 7 days, is available in Turkey. The data
depicted in Tables 1 and 2 include day 14 SAG-M values.
The day 14 results show significant differences compared
to day 0 results. If the freezing of ECs is to be implemented
in Turkey, the AS-3 solution with ACP 215 is definitely
required for the sake of frozen-thawed ECs with a longer
shelf life.
Although the FDA approved their use after storage for
up to 10 years, the exact storage limit of frozen ECs has not
been delineated. Peyrard et al. demonstrated the efficacious
use of frozen ECs after a storage period of 10 to 20 years.
They also reported that, despite recommendations, no
official mandatory time limit regarding the validity period
of rare frozen EC units exists in France (6).
The essential role of frozen ECs has been recognized
and is currently in use in the United States, Germany, the
Netherlands, France, and some other countries (3,6,20).
It has become a part of their national contingency plans,
which include military conflicts, bioterrorism, epidemics,
pandemics, and natural disasters.
Many reports related to the clinical use of frozen ECs
have been published in recent years. For example, in
France, 1957 ECs have been thawed and transfused since
1994, among which 118 were cryopreserved for ≥10 years
and 8 for ≥20 years. Regarding these transfused ECs, no
clinical or biologic evidence of hemolysis of thawed ECs
or transfusion reactions have been reported (6). Currently,
Australian troops deployed in Afghanistan are supported
by the Dutch military blood reserves in that area. They
were supplied 132 frozen-thawed ECs, 75 deep-frozen
plasma units, and 22 frozen-thawed platelet units for the
treatment of 17 casualties. Afterwards, the Australian
Defence Force and the Australian Red Cross blood
service started to investigate the applicability of frozen
blood products for therapeutic purposes to their national
regulatory framework (20).
Although a worst-case scenario had become true
in the Gölcük earthquake, its overall effects on medical
infrastructure and related effects on the casualties have
not been reported yet. Abolghasemi et al. reported that
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during the earthquake in Bam, almost all medical facilities
were damaged as thousand were killed and injured (21).
Thus, strategic plans for all worst-case scenarios have
been developed, involving vigilant and mobile systems for
frozen ECs for the Turkish National Defense and National
Blood Crisis Policy.
Criticism regarding the cost of technical equipment
and all additional requirements may limit the use of frozen
ECs. This cost, however, seems negligible under austere
circumstances where there are no applicable alternatives

to frozen ECs. Lessons learned by the Turkish military
indicate that saving lives far outweighs the cost of all
efforts.
A huge body of literature data and experience has been
already gathered over the years on the preparation, storage,
and use of ECs. Given the earthquake-prone and strategic
location of Turkey, there is a clear and urgent need to
establish both military and civilian frozen EC stocks with
the cooperation of the Turkish Armed Forces, the Turkish
Red Crescent, and other related organizations.
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